DaVita and Fresenius are best positioned to capture the incremental profits from home therapy.
UnitedHealth and CVS are trading at compelling discounts to what we think they’re worth.
This will likely be a more onerous transition year than originally anticipated.
We think the company's advantages will protect shareholder returns over the long run.
The near $1.5 billion purchase of North Carolina's Mission Health gives the narrow-moat firm an immediately dominant presence in the area.
Its place at the intersection of purchasing and analytics creates a narrow moat.